Top Stories

Alleged N4bn fraud: Court orders Obiano to face trial

EDO STATE: I will run an inclusive government,  Ighodalo assures CSOs

Food security: Poultry industry contributes over 25% to Nigeria’s GDP — FG

Damagum remains PDP acting Chairman until…

LGBT Ghanaians await court ruling on restrictive new law

Binance working closely with Nigeria authorities to resolve executive’s detention -CEO says

Remdesivir turns out to do little to prevent deaths from COVID-19 – WHO study

vaccines

Remdesivir turns out to do little to prevent deaths from COVID-19 – WHO study

By Admin
The antiviral drug Remdesivir, considered one of the most promising COVID-19 treatments, turns out to do little to prevent deaths from the disease, according to a WHO-backed study.

Remdesivir, which was part of the experimental cocktail given to US President Donald Trump when he caught the new coronavirus last month, was one of several reviewed in a large study of more than 11,000 people across 30 countries.

remdesivir
WHO logo

The drug “appeared to have little or no effect on hospitalised COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay,” said the study posted online late Thursday.

The data, which has yet to be peer-reviewed or published in a scientific journal, seems to contradict at least two major US studies that have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.

Washington authorised the emergency use of the medicine, made by US pharmaceutical company Gilead Sciences and originally intended as a treatment for Ebola — on May 1, followed by a range of other countries and the European Union.

AFP